Serum fibrinogen/fibrin degradation products in patients with ovarian carcinoma.
Fibrinogen/fibrin degradation products (FDP) in the serum of 50 patients with ovarian carcinoma was examined by Nyléhn's immunochemical method. FDP were rarely found in early but frequently in advanced stages of ovarian tumours. With successful treatment, FDP decreased; otherwise persistently high FDP concentrations were observed in the serum. The determination serum FDP might be a valuable aid in assessing the effect of treatment.
D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000097:blood / Q000188:drug therapy / Q000532:radiotherapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D003536:Cystadenocarcinoma / Q000097:blood / Q000188:drug therapy / Q000532:radiotherapy; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005455:Fluorescent Antibody Technique; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000532:radiotherapy
D005338:Fibrin Fibrinogen Degradation Products; D003520:Cyclophosphamide; D008558:Melphalan